91511-38-5

Basic information

• Product Name: 2H-Tetrazole-5-carboxylicacid,2-methyl-,ethylester(6CI,9CI)
• Synonyms: 2H-Tetrazole-5-carboxylicacid,2-methyl-,ethylester(6CI,9CI);ethyl 2-Methyl-2H-tetrazole-5-carboxylate
• CAS NO: 91511-38-5
• Molecular Formula: C₅H₈N₄O₂
• Molecular Weight: 156.14262
• Product Categories: GLYCINESCAFFOLD
• Mol File: 91511-38-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 104.5-105.5 °C(Press: 2 Torr)
• Appearance: /
• Density: 1.2172 g/cm3(Temp: 25 °C)
• PKA: 0.81±0.10(Predicted)
• CAS DataBase Reference: 2H-Tetrazole-5-carboxylicacid,2-methyl-,ethylester(6CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Tetrazole-5-carboxylicacid,2-methyl-,ethylester(6CI,9CI)(91511-38-5)
• EPA Substance Registry System: 2H-Tetrazole-5-carboxylicacid,2-methyl-,ethylester(6CI,9CI)(91511-38-5)

Safety Data

• Hazardous Substances Data: 91511-38-5(Hazardous Substances Data)

Usage

General Description

2H-Tetrazole-5-carboxylic acid, 2-methyl-, ethyl ester is a chemical compound with the molecular formula C7H10N4O2. It is an organic compound that belongs to the class of tetrazoles. 2H-Tetrazole-5-carboxylicacid,2-methyl-,ethylester(6CI,9CI) is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It has unique properties that make it useful in various fields, including medicinal chemistry and materials science. Additionally, it is a versatile intermediate that can be further modified to produce a wide range of derivatives with different properties and applications.

Upstream product

• 13175-00-3 2-methyl-2H-1,2,3,4-tetrazole-5-carboxylic acid 
• 64-17-5 ethanol 
• 55408-10-1 1H-tetrazole-5-carboxylic acid ethyl ester 
• 74-88-4 methyl iodide 
• 186581-53-3 diazomethane 

Downstream Products

• 114841-40-6 methyl (2-methyltetrazol-5-yl) ketone 
• 55408-40-7 (2-methyl-2H-tetrazol-5-yl)methanol 
• 101092-47-1 (2-methyl-2H-tetrazol-5-yl)-diphenyl-methanol 
• 118765-92-7 bis-biphenyl-4-yl-(2-methyl-2H-tetrazol-5-yl)-methanol 
• 13175-00-3 2-methyl-2H-1,2,3,4-tetrazole-5-carboxylic acid 
• 77689-87-3 1-methyl-1H-tetrazole-5-carboxylic acid 

Relevant articles and documents

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy

Hypercontractility of the cardiac sarcomere may be essential for the underlying pathological hypertrophy and fibrosis in genetic hypertrophic cardiomyopathies. Aficamten (CK-274) is a novel cardiac myosin inhibitor that was discovered from the optimization of indoline compound 1. The important advancement of the optimization was discovery of an Indane analogue (12) with a less restrictive structure-activity relationship that allowed for the rapid improvement of drug-like properties. Aficamten was designed to provide a predicted human half-life (t1/2) appropriate for once a day (qd) dosing, to reach steady state within two weeks, to have no substantial cytochrome P450 induction or inhibition, and to have a wide therapeutic window in vivo with a clear pharmacokinetic/pharmacodynamic relationship. In a phase I clinical trial, aficamten demonstrated a human t1/2 similar to predictions and was able to reach steady state concentration within the desired two-week window.

DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS

Provided are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt, thereof for use in methods of treatment heart diseases through cardiac sarcomere inhibtion.

QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS

The present invention relates to novel quinolones of Formula I that inhibit inducible NOS synthase together with methods of synthesizing and using the compounds including methods for inhibiting or modulating nitric oxide synthesis and/or lowering nitric oxide levels in a patient by administering the compounds for the treatment of disease.